About BIA Separations
BIA Separations is a Healthcare company based in Villach (Austria) founded in 1998, and was acquired by Sartorius in October 2020. Monolithic chromatographic columns are developed using Convective Interaction Media technology. BIA Separations has raised $1.69 million across 2 funding rounds from investors including Sartorius, European Union and Meta Group. The company has 2 employees. BIA Separations offers products and services including CIMmultus®, PATfix Analytical Platforms, and In-line Lysis System. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Chromatography. Its legal entity is BIA SEPARATIONS INC.
Company details
BIA Separations was established in 1998 in Villach, Austria, within the biotechnology sector. Proprietary short monolithic chromatographic columns are manufactured and distributed for laboratory and industrial use, relying on Convective Interaction Media (CIM) technology. These columns facilitate purification of large biomolecules, including viral vectors, vaccines, plasmid DNA, and proteins such as immunoglobulins G and M. Operations support research, pilot-scale, and production applications across biotechnology processes.
- Headquarters Villach, Austria
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website biaseparations.com
- Social LinkedIn Facebook
- Acquired by Sartorius (Oct 2020)
- Legal Name Bia Separations Inc
Products & Services of BIA Separations
BIA Separations offers a comprehensive portfolio of products and services, including CIMmultus®, PATfix Analytical Platforms, and In-line Lysis System.
Columns for efficient purification of large biomolecules in bioprocessing.
Platforms for process development and analysis of biomolecules like pDNA and mRNA.
System for nucleic acid extraction and purification in biomanufacturing.
Funding Insights of BIA Separations
BIA Separations has successfully raised a total of $1.69M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $390.05 thousand completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.69M
- Total Rounds 2
- Last Round Grant — $390,053
- First Round $1.69M
(Sep 2015)
- Investors Count 2
All 2 funding rounds of BIA Separations with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $390,053 | Grant | – | – | |
| Sep 2015 | $1.69M | Private Equity Round | – | META Group | – |
3 investors in total: 3 institutional.
Investors in BIA Separations
BIA Separations has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Sartorius, European Union and Meta Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech & Life-Sciences focused Seed to Growth stage VC firm investing in Europe | 1993 | meta-group.com | Terni, Italy | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Laboratory and biopharmaceutical equipment is developed for production processes. | 1870 | sartorius.com | Gottingen, Germany |
Investor details for BIA Separations
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BIA Separations
4 dated milestones of BIA Separations across 24 years, from founding to its latest funding, stage changes and deals.
- Founded BIA Separations is founded.
- Funding First funding round of $1.7M.
- Exit Acquired by Sartorius.
- Funding Latest funding round, Grant, of $390K.
Web traffic of BIA Separations
The website of BIA Separations (biaseparations.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▼ 35.2% vs previous month
Websites whose visitors overlap most with BIA Separations. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| zirchrom.com | 88% | 2.9K | #7,293,899 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bia Separations
Complete news archive for BIA Separations
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BIA Separations
BIA Separations was founded in 1998 and raised its 1st funding round 17 years after it was founded.
BIA Separations is headquartered in Villach, Austria. It is registered at Villach, Karnten, Austria.
BIA Separations is a funded company, having raised a total of $1.69M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $1.69M, raised on Sep 2015.
BIA Separations has 2 employees.
BIA Separations was established in 1998 in Villach, Austria, within the biotechnology sector. Proprietary short monolithic chromatographic columns are manufactured and distributed for laboratory and industrial use, relying on Convective Interaction Media (CIM) technology. These columns facilitate purification of large biomolecules, including viral vectors, vaccines, plasmid DNA, and proteins such as immunoglobulins G and M. Operations support research, pilot-scale, and production applications across biotechnology processes.
BIA Separations offers CIMmultus®, PATfix Analytical Platforms, and In-line Lysis System.
BIA Separations has 3 investors. Key investors include Sartorius, European Union, and Meta Group.
BIA Separations operates through Bia Separations Inc.
Yes. BIA Separations was acquired by Sartorius in October 2020.